Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
Neurological Clinic, Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, Ancona, Italy.
Mult Scler Relat Disord. 2021 Sep;54:103126. doi: 10.1016/j.msard.2021.103126. Epub 2021 Jun 30.
Inflamma-miRs are a group of microRNAs involved in the regulation of innate and adaptive immune responses. Increasing evidence support the contribution of dysregulated inflamma-miRs in the pathogenesis of multiple sclerosis. The aim of this study was to evaluate the expression of selected inflamma-miRs, i.e., miR-34a-5p, -125a-5p, -146a-5p, and -155, in relapsing-remitting multiple sclerosis (RRMS) and their modulation after treatment with dimethyl fumarate (DMF).
Circulating levels of microRNAs involved in inflammatory response (inflamma-miRs) were compared between healthy controls (CTRs, n=21) and patients with RRMS (n=24) who started treatment with DMF.
Plasma levels of miR-34a (p<0.001) and miR-125a-5p (p=0.034) were higher, whereas miR-146a-5p levels were lower (p=0.041) in RRMS patients compared to CTRs. Circulating miR-125a-5p (p=0.001), miR-146a-5p (p<0.001), and miR-155 (p=0.013) were reduced after 4-month treatment with DMF. Among these, baseline and 4-month follow up miR-125a-5p (p=0.028) and miR-146a-5p (p=0.042) levels were related to disability progression.
Circulating inflamma-miRs could represent candidate tools to predict MS clinical course and evaluate the effectiveness of disease-modifying treatments in RRMS.
炎性 microRNAs 是一组参与先天和适应性免疫反应调节的 microRNAs。越来越多的证据支持失调的炎性 microRNAs 对多发性硬化症发病机制的贡献。本研究旨在评估选定的炎性 microRNAs（即 miR-34a-5p、-125a-5p、-146a-5p 和 -155）在复发缓解型多发性硬化症（RRMS）中的表达及其在二甲基富马酸（DMF）治疗后的调节。
比较了健康对照组（CTR，n=21）和开始 DMF 治疗的 RRMS 患者（n=24）之间参与炎症反应的 microRNAs（炎性 microRNAs）的循环水平。
与 CTR 相比，RRMS 患者的血浆 miR-34a（p<0.001）和 miR-125a-5p（p=0.034）水平升高，而 miR-146a-5p 水平降低（p=0.041）。经过 4 个月的 DMF 治疗后，循环 miR-125a-5p（p=0.001）、miR-146a-5p（p<0.001）和 miR-155（p=0.013）降低。其中，基线和 4 个月随访时的 miR-125a-5p（p=0.028）和 miR-146a-5p（p=0.042）水平与残疾进展相关。
循环炎性 microRNAs 可能成为预测 MS 临床病程和评估 RRMS 疾病修饰治疗效果的候选工具。
